Focal therapy for prostate cancer 1996: Maximizing outcome

被引:40
作者
Carroll, PR
Presti, JC
Small, E
Roach, M
机构
[1] UNIV CALIF SAN FRANCISCO, DEPT RADIAT ONCOL, SCH MED, SAN FRANCISCO, CA 94143 USA
[2] UNIV CALIF SAN FRANCISCO, DIV MED ONCOL, SCH MED, SAN FRANCISCO, CA 94143 USA
[3] UNIV CALIF SAN FRANCISCO, MT ZION CANC CTR, PROGRAM UROL ONCOL, SAN FRANCISCO, CA 94143 USA
[4] SAN FRANCISCO VET ADM MED CTR, SAN FRANCISCO, CA USA
关键词
D O I
10.1016/S0090-4295(97)00174-X
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives. To summarize improvements in patient selection and the results of focal therapy for the management of localized prostate cancer. Methods. A contemporary series of patients managed with wide surgical excision, radiation therapy (three-dimensional conformal radiation, interstitial radiation, and charged-particle or proton therapy), and cryotherapy were reviewed. Results. We used preoperative cancer grade, transrectal ultrasound, and serum prostate-specific antigen (PSA) in all patients, and cross-sectional imaging and bone scans in selected patients to allow for reasonably accurate cancer staging and selection of patients most likely to be cured by radical prostatectomy or radiation. In patients with extracapsular extension of prostate cancer, wide surgical excision and achievement of a clear surgical margin had therapeutic value. Newer radiation techniques resulted in a higher likelihood of prostate cancer control than previous techniques. Cryotherapy for patients with stages T1 through 3 prostate cancer was associated with a posttreatment undetectable PSA rate of 48% and a positive biopsy rate of 23%. Conclusions. Patients with organ-confined and, therefore, curable prostate cancer can be identified. Well-performed radical prostatectomy, radiation, and cryotherapy are alternative treatments for the management of localized prostate cancer. (C) 1997 by Elsevier Science Inc.
引用
收藏
页码:84 / 94
页数:11
相关论文
共 67 条
[1]   ANALYSIS OF RISK-FACTORS ASSOCIATED WITH PROSTATE-CANCER EXTENSION TO THE SURGICAL MARGIN AND PELVIC NODE METASTASIS AT RADICAL PROSTATECTOMY [J].
ACKERMAN, DA ;
BARRY, JM ;
WICKLUND, RA ;
OLSON, N ;
LOWE, BA .
JOURNAL OF UROLOGY, 1993, 150 (06) :1845-1850
[2]  
ALAKURA K, 1993, CANCER, V71, P2782
[3]   PROSTATE-CANCER - US-GUIDED PERCUTANEOUS CRYOABLATION WORK-IN-PROGRESS [J].
BAHN, DK ;
LEE, F ;
SOLOMON, MH ;
GONTINA, H ;
KLIONSKY, DL ;
LEE, FT .
RADIOLOGY, 1995, 194 (02) :551-556
[4]  
Bander Neil H., 1996, Journal of Urology, V155, p610A
[5]   LATE RECTAL BLEEDING FOLLOWING COMBINED X-RAY AND PROTON HIGH-DOSE IRRADIATION FOR PATIENTS WITH STAGES T3-T4 PROSTATE CARCINOMA [J].
BENK, VA ;
ADAMS, JA ;
SHIPLEY, WU ;
URIE, MM ;
MCMANUS, PL ;
EFIRD, JT ;
WILLETT, CG ;
GOITEIN, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1993, 26 (03) :551-557
[6]  
Bermudez Maria-Amelia, 1995, International Journal of Radiation Oncology Biology Physics, V32, P253, DOI 10.1016/0360-3016(95)97886-6
[7]   PROSTATE-SPECIFIC ANTIGEN BASED DISEASE-CONTROL FOLLOWING ULTRASOUND-GUIDED (125)IODINE IMPLANTATION FOR STAGE T1/T2 PROSTATIC-CARCINOMA [J].
BLASKO, JC ;
WALLNER, K ;
GRIMM, PD ;
RAGDE, H .
JOURNAL OF UROLOGY, 1995, 154 (03) :1096-1099
[8]   DETECTION OF OCCULT MICROMETASTASES IN THE BONE-MARROW OF PATIENTS WITH PROSTATE CARCINOMA [J].
BRETTON, PR ;
MELAMED, MR ;
FAIR, WR ;
COTE, RJ .
PROSTATE, 1994, 25 (02) :108-114
[9]  
BRUCHOVSKY N, 1990, CANCER RES, V50, P2275
[10]  
CARROLL PR, 1988, SEMIN UROL, V6, P332